Development of Novel Pharmacotherapeutics for Tobacco Dependence: Progress and Future Directions
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The vast majority of tobacco smokers seeking to quit will relapse within the first month of abstinence. Currently available smoking cessation agents have limited utility in increasing rates of smoking cessation and in some cases there are notable safety concerns related to their use. Hence, there is a pressing need to develop safer and more efficacious smoking cessation medications. METHODS: Here, we provide an overview of current efforts to develop new pharmacotherapeutic agents to facilitate smoking cessation, identified from ongoing clinical trials and published reports. RESULTS: Nicotine is considered the major addictive agent in tobacco smoke, and the vast majority of currently available smoking cessation agents act by modulating nicotinic acetylcholine receptor (nAChR) signaling. Accordingly, there is much effort directed toward developing novel small molecule therapeutics and biological agents such as nicotine vaccines for smoking cessation that act by modulating nAChR activity. Our increasing knowledge of the neurobiology of nicotine addiction has revealed new targets for novel smoking cessation therapeutics. Indeed, we highlight many examples of novel small molecule drug development around non-nAChR targets. Finally, there is a growing appreciation that medications already approved for other disease indications could show promise as smoking cessation agents, and we consider examples of such repurposing efforts. CONCLUSION: Ongoing clinical assessment of potential smoking cessation agents offers the promise of new effective medications. Nevertheless, much of our current knowledge of molecular mechanisms of nicotine addiction derived from preclinical studies has not yet been leveraged for medications development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in relation to smoking: 50 years' observations on male British doctors
Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004) · BMJ · doi:10.1136/bmj.38142.554479.ae · Cited by 2,920
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease
Thorgeirsson, T. E., Geller, F., Sulem, P., Rafnar, T., Wiste, A., Magnusson, K. P., Manolescu, A., Thorleifsson, G., Stefansson, H., Ingason, A., et al. (2008) · Nature · doi:10.1038/nature06846 · Cited by 1,523 · cited 2×
“, 2008; Wang, Broderick, Matakidou, Eisen, & Houlston, 2010), likely reflecting higher levels of tobacco dependence in individuals carrying risk alleles and consequently greater exposure to carcinogens contained in tobacco smoke (Le Marchand et al., 2008; Thorgeirsson et al., 2008).”
BackgroundPicciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., Fuxe, K., & Changeux, J.-P. (1998) · Nature · doi:10.1038/34413 · Cited by 1,320 · cited 1×
“brain, abolishes sensitivity to the reinforcing effects of nicotine (Picciotto et al., 1998).”
BackgroundAmos, C. I., Wu, X., Broderick, P., Gorlov, I. P., Gu, J., Eisen, T., Dong, Q., Zhang, Q., Gu, X., Vijayakrishnan, J., et al. (2008) · Nature Genetics · doi:10.1038/ng.109 · Cited by 1,310
Hung, R. J., McKay, J. D., Gaborieau, V., Boffetta, P., Hashibe, M., Zaridze, D., Mukeria, A., Szeszenia-Dabrowska, N., Lissowska, J., Rudnai, P., et al. (2008) · Nature · doi:10.1038/nature06885 · Cited by 1,275 · cited 2×
“The D398N allele is also a major risk factor for lung cancer and COPD in smokers (Amos et al., 2008; Hung et al., 2008; Wang, Broderick, Matakidou, Eisen, & Houlston, 2010), likely reflecting higher levels of tobacco dependence in individuals carrying risk alleles and consequently greater…”
BackgroundEstimates of global mortality attributable to smoking in 2000
Ezzati, M., & Lopez, A. D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14338-3 · Cited by 1,247 · cited 1×
“…billion current smokers worldwide will die from smoking-related illnesses, such as chronic obstructive pulmonary disorder (COPD), lung cancer, and cardiovascular disease (Besson et al., 2012; Coe et al., 2005; Doll, Peto, Boreham, & Sutherland, 2004; Ezzati & Lopez, 2003; Mathers & Loncar, 2006).”
BackgroundDamage to the insula disrupts addiction to cigarette smoking
Naqvi, N. H., Rudrauf, D., Damasio, H., & Bechara, A. (2007) · Science · doi:10.1126/science.1135926 · Cited by 1,245
Genome-wide meta-analyses identify multiple loci associated with smoking behavior
The Tobacco and Genetics Consortium (2010) · Nature Genetics · doi:10.1038/ng.571 · Cited by 1,098
Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors
McGehee, D. S., Heath, M. J. S., Gelber, S., Devay, P., & Role, L. W. (1995) · Science · doi:10.1126/science.7569895 · Cited by 1,070
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics
Benowitz, N. L. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094742 · Cited by 979 · cited 1×
“Nevertheless, ~80% of smokers attempting to quit will relapse within the first month of abstinence (Benowitz, 2009).”
Background
Cited by
Systematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
“Owing to the serendipitous observation that it decreased smoking in depressed patients taking this drug, Bupropion was approved for smoking cessation in 1997 (Harmey et al., 2012).”
BackgroundNicotine Replacement Therapy : An Overview
Wadgave, U., & L., N. (2016) · International Journal of Health Sciences · doi:10.12816/0048737 · Cited by 141
The CHRNA5–A3–B4 Gene Cluster and Smoking: From Discovery to Therapeutics
Lassi, G., Taylor, A. E., Timpson, N. J., Kenny, P. J., Mather, R. J., Eisen, T., & Munafò, M. R. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.10.005 · Cited by 85
Self-citationNicotine aversion is mediated by GABAergic interpeduncular nucleus inputs to laterodorsal tegmentum
Wolfman, S. L., Gill, D. F., Bogdanic, F., Long, K., Al-Hasani, R., McCall, J. G., Bruchas, M. R., & McGehee, D. S. (2018) · Nature Communications · doi:10.1038/s41467-018-04654-2 · Cited by 81
Formatting biological big data for modern machine learning in drug discovery
Duran‐Frigola, M., Fernández‐Torras, A., Bertoni, M., & Aloy, P. (2019) · WIREs Computational Molecular Science · doi:10.1002/wcms.1408 · Cited by 25
Metadata
- Authors
- Harmey, D., Griffin, P. R., & Kenny, P. J.
- Venue
- Nicotine & Tobacco Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-09-27
- Volume
- 14
- Issue
- 11
- Pages
- 1300-1318
- ISSN
- 1462-2203 (ISSN-L)
- 1469-994X
- OpenAlex
- W2031417710
- Cited by
- 37
- References
- 72
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of Novel Pharmacotherapeutics for Tobacco Dependence: Progress and Future Directions. https://app.cochat.ai/papers/10.1093/ntr/nts201
- The paper
- Harmey, D., Griffin, P. R., & Kenny, P. J. (2012). Development of Novel Pharmacotherapeutics for Tobacco Dependence: Progress and Future Directions. Nicotine & Tobacco Research. https://doi.org/10.1093/ntr/nts201
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.